SCHEMBL11974013

SCHEMBL11974013

CNN1Cc2ccc(F)cc2C1

nearest known ligand 0.44

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
DPP9 Q86TI2 11/20 0.44
DPP8 Q6V1X1 8/20 0.44
DPP4 P27487 7/20 0.44
DPP7 Q9UHL4 5/20 0.44
KCNH2 Q12809 2/20 0.44
TMEM97 Q5BJF2 2/20 0.44
SIGMAR1 Q99720 2/20 0.44
PITRM1 Q5JRX3 1/20 0.38
NAMPT P43490 4/20 0.37
SLC6A2 P23975 1/20 0.37
SLC6A4 P31645 1/20 0.37
SLC6A3 Q01959 1/20 0.37
HSP90B1 P14625 1/20 0.36
TRAP1 Q12931 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL1028134 0.98 DPP9 (0.43) DPP9DPP8DPP4DPP7KCNH2
SCHEMBL11974589 0.78 DPP8 (0.39) DPP9DPP8DPP4DPP7KCNH2
SCHEMBL10209346 0.77 DPP9 (0.46) DPP9DPP8DPP4DPP7KCNH2
SCHEMBL8228638 0.77 DPP9 (0.47) DPP9DPP8DPP4DPP7KCNH2
Hydrochloric Acid SCHEMBL1026718 0.76 DPP8 (0.38) DPP9DPP8DPP4DPP7KCNH2
SCHEMBL2145007 0.76 CARM1 (0.42) DPP9DPP8DPP7NAMPT
SCHEMBL11973938 0.73 MAOA (0.44) NAMPT
SCHEMBL29824272 0.73 DPP9 (0.56) DPP9DPP8DPP4DPP7NAMPT
SCHEMBL19675161 0.72 DPP9 (0.47) DPP9DPP8DPP4DPP7KCNH2
SCHEMBL19700136 0.72 KCNH2 (0.59) DPP9DPP8DPP4DPP7KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8513235-B2 Homocysteine synthase inhibitor MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-08-20 US disclosed
EP-2486925-A1 THERAPEUTIC AGENT FOR CEREBRAL INFARCTION Mitsubishi Tanabe Pharma Corporation (JP) 2012-08-15 EP disclosed
US-20120196824-A1 THERAPEUTIC AGENT FOR CEREBRAL INFARCTION MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-08-02 US disclosed
WO-2011043479-A1 THERAPEUTIC AGENT FOR CEREBRAL INFARCTION 田辺三菱製薬株式会社 (JP) 2011-04-14 WO disclosed
US-20110034440-A1 HOMOCYSTEINE SYNTHASE INHIBITOR MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-02-10 US disclosed
WO-2009125853-A1 HOMOCYSTEINE SYNTHASE INHIBITOR 田辺三菱製薬株式会社 (JP) 2009-10-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120196824-A1 THERAPEUTIC AGENT FOR CEREBRAL INFARCTION FABP7, TIMP3, MMP11 DPP9 1542/4885DPP8 2320/4885DPP4 1673/4885
US-20110034440-A1 HOMOCYSTEINE SYNTHASE INHIBITOR BHMT, CBS, BHMT2 DPP9 1760/4885DPP8 2916/4885DPP4 3209/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.